Literature DB >> 19767588

Multiple sequence variants in hereditary hemorrhagic telangiectasia cases: illustration of complexity in molecular diagnostic interpretation.

Jamie McDonald1, Friederike Gedge, Allene Burdette, James Carlisle, Changkuoth Jock Bukjiok, Michelle Fox, Pinar Bayrak-Toydemir.   

Abstract

Hereditary hemorrhagic telangiectasia is an autosomal dominant disease caused by mutations in the ACVRL1 and ENG genes characterized by arterio-venous malformations and telangiectases. Over 700 mutations have been described in these two genes, and missense mutations are common. We describe 10 cases in which more than one potentially pathogenic mutation was identified. We report that 8 novel missense mutations, as well as previously reported pathogenic missense mutations, were seen in combination with a second mutation, which raises questions with regards to their respective pathogenicity. Our data and discussion indicate the challenges of classifying missense mutations as pathogenic or benign and the value of co-segregation studies, as well as suggest that there may be hereditary hemorrhagic telangiectasia gene mutations that have only mild phenotypic effects. We present evidence to suggest that four missense mutations (ENG p.G331S, ENG p.L8P, ENG p.P452L and ACVRL1 p.C344R) are pathogenic, two novel mutations (ACVRL1 p.A311T and ENG p.S576G) are neutral, and two previously reported disease-causing mutations are benign or have suspected benign variants (ACVRL1 p.A482V and ENG p.V504M). We conclude that for the purpose of establishing a causative hereditary hemorrhagic telangiectasia mutation in a family proband, all exons and intron/exon borders of both genes should be sequenced and deletion/duplication analysis should be performed unless a mutation that is well-proven to be pathogenic is identified.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19767588      PMCID: PMC2765756          DOI: 10.2353/jmoldx.2009.080148

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  25 in total

1.  Mutational analysis of activin/transforming growth factor-beta type I and type II receptor kinases in human pituitary tumors.

Authors:  F H D'Abronzo; B Swearingen; A Klibanski; J M Alexander
Journal:  J Clin Endocrinol Metab       Date:  1999-05       Impact factor: 5.958

2.  The activin receptor-like kinase 1 gene: genomic structure and mutations in hereditary hemorrhagic telangiectasia type 2.

Authors:  J N Berg; C J Gallione; T T Stenzel; D W Johnson; W P Allen; C E Schwartz; C E Jackson; M E Porteous; D A Marchuk
Journal:  Am J Hum Genet       Date:  1997-07       Impact factor: 11.025

3.  Mutations in endoglin and in activin receptor-like kinase 1 among Danish patients with hereditary haemorrhagic telangiectasia.

Authors:  K Brusgaard; A D Kjeldsen; L Poulsen; H Moss; P Vase; K Rasmussen; T A Kruse; M Hørder
Journal:  Clin Genet       Date:  2004-12       Impact factor: 4.438

4.  Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome).

Authors:  C L Shovlin; A E Guttmacher; E Buscarini; M E Faughnan; R H Hyland; C J Westermann; A D Kjeldsen; H Plauchu
Journal:  Am J Med Genet       Date:  2000-03-06

5.  The natural history of epistaxis in hereditary hemorrhagic telangiectasia.

Authors:  O S AAssar; C M Friedman; R I White
Journal:  Laryngoscope       Date:  1991-09       Impact factor: 3.325

6.  Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1.

Authors:  K A McAllister; K M Grogg; D W Johnson; C J Gallione; M A Baldwin; C E Jackson; E A Helmbold; D S Markel; W C McKinnon; J Murrell
Journal:  Nat Genet       Date:  1994-12       Impact factor: 38.330

Review 7.  Hereditary hemorrhagic telangiectasia: an overview of diagnosis and management in the molecular era for clinicians.

Authors:  Pinar Bayrak-Toydemir; Rong Mao; Susan Lewin; Jamie McDonald
Journal:  Genet Med       Date:  2004 Jul-Aug       Impact factor: 8.822

8.  A newborn with hereditary haemorrhagic telangiectasia and an unusually severe phenotype.

Authors:  Loukas Argyriou; Johannes Wirbelauer; Arvind Dev; Irakli Panchulidze; Moneef Shoukier; Ute Teske; Karim Nayernia
Journal:  Swiss Med Wkly       Date:  2008-07-26       Impact factor: 2.193

9.  Molecular screening of ALK1/ACVRL1 and ENG genes in hereditary hemorrhagic telangiectasia in France.

Authors:  Gaëtan Lesca; Henri Plauchu; Florence Coulet; Sylvain Lefebvre; Ghislaine Plessis; Sylvie Odent; Sophie Rivière; Bruno Leheup; Cyril Goizet; Marie-France Carette; Jean-François Cordier; Stéphane Pinson; Florent Soubrier; Alain Calender; Sophie Giraud
Journal:  Hum Mutat       Date:  2004-04       Impact factor: 4.878

10.  A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4).

Authors:  Carol J Gallione; Gabriela M Repetto; Eric Legius; Anil K Rustgi; Susan L Schelley; Sabine Tejpar; Grant Mitchell; Eric Drouin; Cornelius J J Westermann; Douglas A Marchuk
Journal:  Lancet       Date:  2004-03-13       Impact factor: 79.321

View more
  9 in total

1.  Endothelial chromosome 13 deletion in congenital heart disease-associated pulmonary arterial hypertension dysregulates SMAD9 signaling.

Authors:  Kylie M Drake; Suzy A Comhair; Serpil C Erzurum; Rubin M Tuder; Micheala A Aldred
Journal:  Am J Respir Crit Care Med       Date:  2015-04-01       Impact factor: 21.405

2.  Directional next-generation RNA sequencing and examination of premature termination codon mutations in endoglin/hereditary haemorrhagic telangiectasia.

Authors:  F S Govani; A Giess; I G Mollet; M E Begbie; M D Jones; L Game; C L Shovlin
Journal:  Mol Syndromol       Date:  2013-04-11

Review 3.  'There and Back Again'-Forward Genetics and Reverse Phenotyping in Pulmonary Arterial Hypertension.

Authors:  Emilia M Swietlik; Matina Prapa; Jennifer M Martin; Divya Pandya; Kathryn Auckland; Nicholas W Morrell; Stefan Gräf
Journal:  Genes (Basel)       Date:  2020-11-26       Impact factor: 4.096

4.  Update on molecular diagnosis of hereditary hemorrhagic telangiectasia.

Authors:  Jennifer Richards-Yutz; Kathleen Grant; Elizabeth C Chao; Susan E Walther; Arupa Ganguly
Journal:  Hum Genet       Date:  2010-04-23       Impact factor: 4.132

5.  Fine mapping of the hereditary haemorrhagic telangiectasia (HHT)3 locus on chromosome 5 excludes VE-Cadherin-2, Sprouty4 and other interval genes.

Authors:  Fatima S Govani; Claire L Shovlin
Journal:  J Angiogenes Res       Date:  2010-08-11

Review 6.  Hereditary hemorrhagic telangiectasia: genetics and molecular diagnostics in a new era.

Authors:  Jamie McDonald; Whitney Wooderchak-Donahue; Chad VanSant Webb; Kevin Whitehead; David A Stevenson; Pinar Bayrak-Toydemir
Journal:  Front Genet       Date:  2015-01-26       Impact factor: 4.599

7.  Specific cancer rates may differ in patients with hereditary haemorrhagic telangiectasia compared to controls.

Authors:  Anna E Hosman; Hannah L Devlin; B Maneesha Silva; Claire L Shovlin
Journal:  Orphanet J Rare Dis       Date:  2013-12-20       Impact factor: 4.123

Review 8.  Optimal management of hereditary hemorrhagic telangiectasia.

Authors:  Neetika Garg; Monica Khunger; Arjun Gupta; Nilay Kumar
Journal:  J Blood Med       Date:  2014-10-15

9.  An intron mutation in the ACVRL1 may be associated with a transcriptional regulation defect in a Chinese family with hereditary hemorrhagic telangiectasia.

Authors:  Qian Yu; Xiao-Hui Shen; Ying Li; Rui-Juan Li; Ji Li; Yun-Ya Luo; Su-Fang Liu; Ming-Yang Deng; Min-Fei Pei; Guang-Sen Zhang
Journal:  PLoS One       Date:  2013-02-27       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.